Document Detail

Fibrinolytic parameters, lipid status and lipoprotein(a) in ischemic stroke patients.
MedLine Citation:
PMID:  20229676     Owner:  NLM     Status:  MEDLINE    
INTRODUCTION: Ischemic stroke is the third leading cause of mortality and morbidity in most countries in the world. Impaired fibrinolysis, as well as disordered lipid metabolism have been recognized as risk factors for this disease. OBJECTIVE: To study some of fibrinolytic parameters, lipid status and lipoprotein(a) - Lp(a) in ischemic stroke patients in Serbia and to examine associations between Lp(a) and fibrinolytic parameters. METHODS: Sixty ischemic stroke patients (case group, mean age 63.48 +/- 9.62 years) and 30 age and sex matched healthy controls (control group, mean age 60.2 +/- 7.96 years) were studied. RESULTS: A significantly longer euglobulin clot lysis time (219.7 +/- 78,8 min. vs 183.5 +/- 58,22 min; p = 0.005) and higher levels of plasminogen activator inhibitor-1 (PAI-1) (48.5 +/- 17.1 ng/ml vs 27.1 +/- 10.1 ng/ml; p = 6.2 x 10(-11)), tissue-type plasminogen activator antigen (t-PA) (11.1 +/- 7.14 ng/ml vs 6.0 +/- 3.66 ng/ml; p = 5.2 x 10(-5)) and D-dimer (382.27 +/- 504.22 ng/ml vs 116.12 +/- 88.81 ng/ml; p = 0.0002) were found in cases compared to controls. There were no significant differences in fibrinogen levels (4.30 +/- 0.84 g/l vs 4.09 +/- 0.64 g/l; p = 0.23) or plasminogen activity (92.67 +/- 11.37% vs 96.87 +/- 9.48%; p = 0.085). There was no significant difference in Lp(a) concentration between cases and controls (0.15 +/- 0.11 g/l vs 0.12 +/- 0.11 g/l; p = 0.261). However, in the cases, but not in the controls, multivariate analysis of associations between fibrinolytic parameters and Lp(a) showed the highest correlation between t-PA and PAI-1, and the latent effect of Lp(a) on t-PA and PAI-1. CONCLUSIONS: Our results show that there are important differences in the characteristics of the fibrinolytic mechanism in ischemic stroke patients compared to healthy population. The major differences are prolonged euglobulin clot lysis time and elevated PAI-1 and t-PA antigen in ischemic stroke patients. In addition, Lp(a) appears to be involved in the inhibition offibrinolysis in ischemic disease through a mechanism unrelated to its serum concentrations.
Biljana A Vuckovi?; Mirjana J Djeri?; Tatjana A Ili?; Visnja B Canak; Suncica Lj Koji?-Damjanov; Marija G Zarkov; Velibor S Cabarkapa
Related Documents :
3764966 - Basilar and distal vertebral artery stenosis: long-term follow-up.
9756586 - The camcog: a useful screening instrument for dementia in stroke patients.
20725736 - Nocturia is an independent predictor of severe obstructive sleep apnea in patients with...
9840906 - Inherited dna mutations contributing to thrombotic complications in patients with sickl...
24635926 - Clinical rem sleep behavior disorder and motor subtypes in parkinson's disease: a quest...
1677396 - A subset of acute lymphoblastic leukemia with co-expression of myeloid antigens: preval...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Srpski arhiv za celokupno lekarstvo     Volume:  138 Suppl 1     ISSN:  0370-8179     ISO Abbreviation:  Srp Arh Celok Lek     Publication Date:  2010 Jan 
Date Detail:
Created Date:  2010-03-16     Completed Date:  2010-04-20     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0027440     Medline TA:  Srp Arh Celok Lek     Country:  Serbia    
Other Details:
Languages:  eng     Pagination:  12-7     Citation Subset:  IM    
Department of Haemostasis, Thrombosis and Haematology Diagnostics, Centre for Laboratory Medicine, Clinical Centre of Vojvodina, Novi Sad, Serbia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Antifibrinolytic Agents / blood
Blood Coagulation Tests
Brain Ischemia / blood*,  complications
Fibrin Fibrinogen Degradation Products / analysis
Lipids / blood*
Lipoprotein(a) / blood*
Middle Aged
Plasminogen Activator Inhibitor 1 / blood
Stroke / blood*,  etiology
Tissue Plasminogen Activator / blood
Reg. No./Substance:
0/Antifibrinolytic Agents; 0/Fibrin Fibrinogen Degradation Products; 0/Lipids; 0/Lipoprotein(a); 0/Plasminogen Activator Inhibitor 1; 0/fibrin fragment D; EC Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Is lipoprotein(a) regulating prostaglandin I2-synthesis stimulating plasma factor?
Next Document:  Efficacy and safety of nadroparin and unfractionated heparin for the treatment of venous thromboembo...